[November 27, 2015] |
|
Research and Markets: Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review & Analysis, H2 2015
Research and Markets (http://www.researchandmarkets.com/research/fzmftp/acute_renal)
has announced the addition of the "Acute
Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2015"
report to their offering.
This report provides comprehensive information on the therapeutic
development for Acute Renal Failure (ARF) (Acute Kidney Injury),
complete with comparative analysis at various stages, therapeutics
assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates, and
featured news and press releases. It also reviews key players involved
in the therapeutic development for Acute Renal Failure (ARF) (Acute
Kidney Injury) and special features on late-stage and discontinued
projects.
Key Topics Covered:
-
Snapshot of the global therapeutic landscape of Acute Renal Failure
(ARF) (Acute Kidney Injury)
-
Key pipeline products under drug profile section which includes,
product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
-
Key players involved in the therapeutics development for Acute Renal
Failure (ARF) (Acute Kidney Injury) and enlists all heir major and
minor projects
-
All dormant and discontinued pipeline projects
-
All Acute Renal Failure (ARF) (Acute Kidney Injury) products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
Detailed assessment of monotherapy and combination therapy pipeline
projects
Benefits of this Report:
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and
focus of Indication therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned Include:
-
A1M Pharma AB
-
Adrenomed AG
-
Am-Pharma B.V.
-
Angion Biomedica Corp.
-
Bolder Biotechnology, Inc.
-
Cellmid Limited
-
Complexa, Inc.
-
DiaMedica Inc.
-
Digna Biotech, S.L.
-
DURECT Corporation
-
F. Hoffmann-La Roche Ltd.
-
STATegics, Inc.
-
Thrasos, Inc.
-
Torrent Pharmaceuticals Limited
For more information visit http://www.researchandmarkets.com/research/fzmftp/acute_renal
View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005414/en/
[ Back To TMCnet.com's Homepage ]
|